

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |           |  |
|--|-----------|--|
| <b>(51) International Patent Classification <sup>6</sup> :</b><br><b>C12Q 1/68, G01N 33/53, 33/574</b>   | <b>A1</b> | <b>(11) International Publication Number:</b> <b>WO 99/60161</b><br><b>(43) International Publication Date:</b> 25 November 1999 (25.11.99)  |
| <b>(21) International Application Number:</b> PCT/US99/10498<br><b>(22) International Filing Date:</b> 12 May 1999 (12.05.99)<br><br><b>(30) Priority Data:</b><br>60/086,266      21 May 1998 (21.05.98)      US<br><br><b>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application</b><br>US      60/086,266 (CIP)<br>Filed on      21 May 1998 (21.05.98)<br><br><b>(71) Applicant (for all designated States except US):</b> DIADEXUS LLC [US/US]; 3303 Octavius Drive, Santa Clara, CA 95054 (US).<br><br><b>(72) Inventors; and</b><br><b>(75) Inventors/Applicants (for US only):</b> MACINA, Roberto, A. [AR/US]; 4118 Crescendo Avenue, San Jose, CA 95136 (US). YANG, Fei [CN/US]; Apartment 204, 18375 Caminito Cantilena, San Diego, CA 92128 (US). SUN, Yongming [CN/US]; Apartment 260, 869 S. Winchester Boulevard, San Jose, CA 92128 (US). |           | <b>(74) Agents:</b> LICATA, Jane, Massey et al.; Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US).<br><br><b>(81) Designated States:</b> CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).<br><br><b>Published</b><br><i>With international search report.</i> |
| <b>(54) Title:</b> A NOVEL METHOD OF DIAGNOSING, MONITORING, AND STAGING COLON CANCER<br><br><b>(57) Abstract</b><br><br>The present invention provides a new method for detecting, diagnosing, monitoring, staging, and prognosticating colon cancer.   |           |  |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   |    |  | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | ML | Mali   | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MN | Mongolia                                     | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MR | Mauritania                                   | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MW | Malawi                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | MX | Mexico                                       | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NE | Niger  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NL | Netherlands                                  | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NO | Norway                                       | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | NZ | New Zealand                                  |    |                          |
| CM | Cameroon                 |    |  | PL | Poland                                       |    |                          |
| CN | China                    | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CU | Cuba                     | KZ | Kazakstan                                | RO | Romania                                      |    |                          |
| CZ | Czech Republic           | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| DE | Germany                  | LI | Liechtenstein                            | SD | Sudan  |    |                          |
| DK | Denmark                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| EE | Estonia                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |

A NOVEL METHOD OF DIAGNOSING,  
MONITORING, AND STAGING COLON CANCER

**FIELD OF THE INVENTION**

This invention relates, in part, to newly developed assays for detecting, diagnosing, monitoring, staging, and prognosticating cancers, particularly colon cancer.

**BACKGROUND OF THE INVENTION**

Colon cancer is the second most frequently diagnosed malignancy in the United States. Cancer of the gastrointestinal tract, especially colon cancer, is a highly treatable and often a curable disease when localized to the bowel. However, currently colon cancer is the second most common cause of cancer death. Surgery is the primary treatment and results in cure in approximately 50% of patients. Recurrence following surgery is a major problem and often is the ultimate cause of death. The prognosis of colon cancer is clearly related to the degree of penetration of the tumor through the bowel wall and the presence or absence of nodal involvement. These two characteristics form the basis for all staging systems developed for this disease. Bowel obstruction and bowel perforation are indicators of poor prognosis. Elevated pretreatment serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) also have negative prognostic significance.

Because of the frequency of the disease (approximately 160,000 new cases of colon cancer per year), the identification of high-risk groups, the demonstrated slow growth of primary lesions, the better survival of early-stage lesions, and the relative simplicity and accuracy of screening tests, screening for colon cancer should be a part of routine

- 2 -

care for all adults starting at age 50, especially those with first-degree relatives with colorectal cancer.

Procedures used for detecting, diagnosing, monitoring, staging, and prognosticating colon cancer are of critical importance to the outcome of the patient. For example, patients diagnosed with early colon cancer generally have a much greater five-year survival rate as compared to the survival rate for patients diagnosed with distant metastasized colon cancer. Treatment decisions are usually made in reference to the older Dukes or the Modified Astler-Coller (MAC) classification schema for staging. However, new diagnostic methods which are more sensitive and specific for detecting early colon cancer are clearly needed.

Further, colon cancer patients must be closely monitored following initial therapy and during adjuvant therapy to determine response to therapy and to detect persistent or recurrent disease or metastasis. Thus, there is clearly a need for a colon cancer marker which is more sensitive and specific in detecting colon cancer recurrence.

Another important step in managing colon cancer is to determine the stage of the patient's disease. Stage determination has potential prognostic value and provides criteria for designing optimal therapy. Currently, pathological staging of colon cancer is preferable over clinical staging as pathological staging provides a more accurate prognosis. However, clinical staging would be preferred were the method of clinical staging at least as accurate as pathological staging because it does not depend on an invasive procedure to obtain tissue for pathological evaluation. Staging of colon cancer would be improved by detecting new markers in cells, tissues, or bodily fluids which could differentiate between different stages of invasion.

In the present invention, methods are provided for detecting, diagnosing, monitoring, staging, and

- 3 -

prognosticating colon cancers, particularly colon, stomach, and small intestine cancer, via nine (9) Colon Specific Genes (CSGs). The nine CSGs refer, among other things, to native proteins expressed by the genes comprising the polynucleotide sequences of any of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8 or 9. In the alternative, what is meant by the nine CSGs as used herein, means the native mRNAs encoded by the genes comprising any of the polynucleotide sequences of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8 or 9 or levels of the genes comprising any of the polynucleotide sequences of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8 or 9.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

#### **SUMMARY OF THE INVENTION**

Toward these ends, and others, it is an object of the present invention to provide a method for diagnosing the presence of colon cancer in a patient which comprises measuring levels of CSG in a sample of cells, tissue or bodily fluid from the patient and comparing the measured levels of CSG with levels of CSG in preferably the same cells, tissue, or bodily fluid type of a control, wherein an increase in the measured CSG levels in the patient versus levels of CSG in the control is associated with colon cancer.

Another object of the present invention is to provide a method of diagnosing metastatic colon cancer in a patient which comprises measuring CSG levels in a sample of cells,

- 4 -

tissue, or bodily fluid from the patient and comparing the measured CSG levels with levels of CSG in preferably the same cells, tissue, or bodily fluid type of a control, wherein an increase in measured CSG levels in the patient versus levels of CSG in the control is associated with a cancer which has metastasized.

Another object of the present invention is to provide a method of staging colon cancer in a patient which comprises identifying a patient having colon cancer, measuring levels of CSG in a sample of cells, tissues, or bodily fluid obtained from the patient, and comparing the measured CSG levels with levels of CSG in preferably the same cells, tissue or bodily fluid type of a control. An increase in measured CSG levels in the patient versus CSG levels in the control can be associated with a cancer which is progressing while a decrease or equivalent level of CSG measured in the patient versus the control can be associated with a cancer which is regressing or in remission.

Another object of the present invention is to provide a method of monitoring colon cancer in a patient for the onset of metastasis. The method comprises identifying a patient having colon cancer that is not known to have metastasized, periodically measuring levels of CSG in a sample of cells, tissues, or bodily fluid obtained from the patient, and comparing the measured CSG levels with levels of CSG in preferably the same cells, tissue, or bodily fluid type of a control, wherein an increase in measured CSG levels versus control CSG levels is associated with a cancer which has metastasized.

Yet another object of the present invention is to provide a method of monitoring the change in stage of colon cancer in a patient which comprises identifying a patient having colon cancer, periodically measuring levels of CSG in a sample of cells, tissue, or bodily fluid obtained from the patient, and comparing the measured CSG levels with levels of

- 5 -

CSG in preferably the same cells, tissues, or bodily fluid type of a control wherein an increase in measured CSG levels versus the control CSG levels is associated with a cancer which is progressing and a decrease in the measured CSG levels versus the control CSG levels is associated with a cancer which is regressing or in remission.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

#### DESCRIPTION OF THE INVENTION

The present invention relates to diagnostic assays and methods, both quantitative and qualitative for detecting, diagnosing, monitoring, staging, and prognosticating cancers by comparing levels of CSG with those of CSG in a normal human control. What is meant by "levels of CSG" as used herein, means levels of the native protein expressed by the genes comprising the polynucleotide sequence of any of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9. In the alternative, what is meant by "levels of CSG" as used herein, means levels of the native mRNA encoded by any of the genes comprising any of the polynucleotide sequences of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9 or levels of the gene comprising any of the polynucleotide sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9. Such levels are preferably measured in at least one of, cells, tissues and/or bodily fluids, including determination of normal and abnormal levels. Thus, for instance, a diagnostic assay in accordance with the invention for

- 6 -

diagnosing over-expression of any one of the CSG proteins compared to normal control bodily fluids, cells, or tissue samples may be used to diagnose the presence of cancers, including colon cancer. Any of the nine CSGs may be measured alone in the methods of the invention, or all together or any combination of the nine.

By "control" it is meant a human patient without cancer and/or non cancerous samples from the patient, also referred to herein as a normal human control; in the methods for diagnosing or monitoring for metastasis, control may also include samples from a human patient that is determined by reliable methods to have colon cancer which has not metastasized.

All the methods of the present invention may optionally include measuring the levels of other cancer markers as well as CSG. Other cancer markers, in addition to CSG, useful in the present invention will depend on the cancer being tested and are known to those of skill in the art.

#### **Diagnostic Assays**

The present invention provides methods for diagnosing the presence of colon cancer by analyzing for changes in levels of CSG in cells, tissues or bodily fluids compared with levels of CSG in cells, tissues or bodily fluids of preferably the same type from a normal human control, wherein an increase in levels of CSG in the patient versus the normal human control is associated with the presence of colon cancer. Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the patient being tested has cancer is one in which cells, tissues, or bodily fluid levels of the cancer marker, such as CSG, are at least two times higher, and most preferably are at least five times higher, than in preferably the same cells, tissues, or bodily fluid of a normal human control.

The present invention also provides a method of diagnosing metastatic colon cancer in a patient having colon



- 7 -

cancer which has not yet metastasized for the onset of metastasis. In the method of the present invention, a human cancer patient suspected of having colon cancer which may have metastasized (but which was not previously known to have metastasized) is identified. This is accomplished by a variety of means known to those of skill in the art. For example, in the case of colon cancer, patients are typically diagnosed with colon cancer following traditional detection methods.

In the present invention, determining the presence of CSG level in cells, tissues, or bodily fluid, is particularly useful for discriminating between colon cancer which has not metastasized and colon cancer which has metastasized. Existing techniques have difficulty discriminating between colon cancer which has metastasized and colon cancer which has not metastasized and proper treatment selection is often dependent upon such knowledge.

In the present invention, the cancer marker levels measured in such cells, tissues, or bodily fluid is CSG, and are compared with levels of CSG in preferably the same cells, tissue, or bodily fluid type of a normal human control. That is, if the cancer marker being observed is just CSG in serum, this level is preferably compared with the level of CSG in serum of a normal human patient. An increase in the CSG in the patient versus the normal human control is associated with colon cancer which has metastasized.

Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the cancer in the patient being tested or monitored has metastasized is one in which cells, tissues, or bodily fluid levels of the cancer marker, such as CSG, are at least two times higher, and most preferable are at least five times higher, than in preferably the same cells, tissues, or bodily fluid of a normal patient.

- 8 -

Normal human control as used herein includes a human patient without cancer and/or non cancerous samples from the patient; in the methods for diagnosing or monitoring for metastasis, normal human control may also include samples from a human patient that is determined by reliable methods to have colon cancer which has not metastasized.

**Staging**

The invention also provides a method of staging colon cancer in a human patient.

The method comprises identifying a human patient having such cancer; analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG. Then, the method compares CSG levels in such cells, tissues, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of CSG is associated with a cancer which is regressing or in remission.

**Monitoring**

Further provided is a method of monitoring colon cancer in a human having such cancer for the onset of metastasis. The method comprises identifying a human patient having such cancer that is not known to have metastasized; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing the CSG levels in such cells, tissue, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

Further provided by this inventions is a method of monitoring the change in stage of colon cancer in a human having such cancer. The method comprises identifying a human patient having such cancer; periodically analyzing a sample

of cells, tissues, or bodily fluid from such patient for CSG; comparing the CSG levels in such cells, tissue, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease in the levels of CSG is associated with a cancer which is regressing in stage or in remission.

Monitoring such patient for onset of metastasis is periodic and preferably done on a quarterly basis. However, this may be more or less frequent depending on the cancer, the particular patient, and the stage of the cancer.

#### **Assay Techniques**

Assay techniques that can be used to determine levels of gene expression, such as CSG of the present invention, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, reverse transcriptase PCR (RT-PCR) assays, immunohistochemistry assays, *in situ* hybridization assays, competitive-binding assays, Western Blot analyses and ELISA assays. Among these, ELISAs are frequently preferred to diagnose a gene's expressed protein in biological fluids. An ELISA assay initially comprises preparing an antibody, if not readily available from a commercial source, specific to CSG, preferably a monoclonal antibody. In addition a reporter antibody generally is prepared which binds specifically to CSG. The reporter antibody is attached to a detectable reagent such as radioactive, fluorescent or enzymatic reagent, for example horseradish peroxidase enzyme or alkaline phosphatase.

To carry out the ELISA, antibody specific to CSG is incubated on a solid support, e.g., a polystyrene dish, that binds the antibody. Any free protein binding sites on the dish are then covered by incubating with a non-specific

- 10 -

protein such as bovine serum albumin. Next, the sample to be analyzed is incubated in the dish, during which time CSG binds to the specific antibody attached to the polystyrene dish. Unbound sample is washed out with buffer. A reporter antibody specifically directed to CSG and linked to horseradish peroxidase is placed in the dish resulting in binding of the reporter antibody to any monoclonal antibody bound to CSG. Unattached reporter antibody is then washed out. Reagents for peroxidase activity, including a colorimetric substrate are then added to the dish. Immobilized peroxidase, linked to CSG antibodies, produces a colored reaction product. The amount of color developed in a given time period is proportional to the amount of CSG protein present in the sample. Quantitative results typically are obtained by reference to a standard curve.

A competition assay may be employed wherein antibodies specific to CSG attached to a solid support and labeled CSG and a sample derived from the host are passed over the solid support and the amount of label detected attached to the solid support can be correlated to a quantity of CSG in the sample. Nucleic acid methods may be used to detect CSG mRNA as a marker for colon cancer. Polymerase chain reaction (PCR) and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASABA), can be used to detect malignant cells for diagnosis and monitoring of various malignancies. For example, reverse-transcriptase PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other mRNA species. In RT-PCR, an mRNA species is first reverse transcribed to complementary DNA (cDNA) with use of the enzyme reverse transcriptase; the cDNA is then amplified as in a standard PCR reaction. RT-PCR can thus reveal by amplification the presence of a single species of mRNA. Accordingly, if the mRNA is highly specific for the cell that produces it, RT-PCR

- 11 -

can be used to identify the presence of a specific type of cell.

Hybridization to clones or oligonucleotides arrayed on a solid support (i.e., gridding) can be used to both detect the expression of and quantitate the level of expression of that gene. In this approach, a cDNA encoding the CSG gene is fixed to a substrate. The substrate may be of any suitable type including but not limited to glass, nitrocellulose, nylon or plastic. At least a portion of the DNA encoding the CSG gene is attached to the substrate and then incubated with the analyte, which may be RNA or a complementary DNA (cDNA) copy of the RNA, isolated from the tissue of interest.

Hybridization between the substrate bound DNA and the analyte can be detected and quantitated by several means including but not limited to radioactive labeling or fluorescence labeling of the analyte or a secondary molecule designed to detect the hybrid. Quantitation of the level of gene expression can be done by comparison of the intensity of the signal from the analyte compared with that determined from known standards. The standards can be obtained by *in vitro* transcription of the target gene, quantitating the yield, and then using that material to generate a standard curve.

The above tests can be carried out on samples derived from a variety of patients' cells, bodily fluids and/or tissue extracts (homogenates or solubilized tissue) such as from tissue biopsy and autopsy material. Bodily fluids useful in the present invention include blood, urine, saliva, or any other bodily secretion or derivative thereof. Blood can include whole blood, plasma, serum, or any derivative of blood.

#### EXAMPLES

The present invention is further described by the following examples. These examples are provided solely to illustrate the invention by reference to specific embodiments.

- 12 -

These exemplifications, while illustrating certain specific aspects of the invention, do not portray the limitations or circumscribe the scope of the disclosed invention.

**Example 1: CSGs**

Searches were carried out and CSGs identified using the following Search Tools as part of the LIFESEQ® database available from Incyte Pharmaceuticals, Palo Alto, CA:

1. Library Comparison (compares one library to one other library) allows the identification of clones expressed in tumor and absent or expressed at a lower level in normal tissue.

2. Subsetting is similar to library comparison but allows the identification of clones expressed in a pool of libraries and absent or expressed at a lower level in a second pool of libraries.

3. Transcript Imaging lists all of the clones in a single library or a pool of libraries based on abundance. Individual clones can then be examined using Electronic Northern to determine the tissue sources of their component ESTs.

4. Protein Function: Incyte has identified subsets of ESTs with a potential protein function based on homologies to known proteins. Some examples in this database include Transcription Factors and Proteases. We identified some leads by searching in this database for clones whose component ESTs showed disease specificity.

Electronic subtractions, transcript imaging and protein function searches were used to identify clones, whose component ESTs were exclusively or more frequently found in libraries from specific tumors. Individual candidate clones were examined in detail by checking where each EST originated.

**Table 1: CSGs**

| SEQ ID<br>NO: | Clone ID # | Gene ID # |                    |
|---------------|------------|-----------|--------------------|
| 1             | 238330     | 242807    | Transcript Imaging |
| 2             | 1285234    | 239588    | Subsetting         |
| 3             | 1341701    | 29634     | Transcript Imaging |
| 4             | 816257     | 233421    | Subsetting         |
| 5             | 775133     | 245080    | Subsetting         |
| 6             | 1335450    | 245811    | Subsetting         |
| 7             | 2348122    | 233711    | Transcript Imaging |
| 8             | 3228674    | 230273    | Subsetting         |
| 9             | 1632174    | 229022    | Transcript Imaging |

The following example was carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. Routine molecular biology techniques of the following example can be carried out as described in standard laboratory manuals, such as Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).

#### **Example 2: Relative Quantitation of CSG Gene Expression**

Real-Time quantitative PCR with fluorescent Taqman probes is a quantitation detection system utilizing the 5'-3' nuclease activity of Taq DNA polymerase. The method uses an internal fluorescent oligonucleotide probe (Taqman) labeled with a 5' reporter dye and a downstream, 3' quencher dye. During PCR, the 5'-3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected by the laser detector of the Model 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA).



- 15 -

Amplification of an endogenous control is used to standardize the amount of sample RNA added to the reaction and normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or 18S ribosomal RNA (rRNA) is used as this endogenous control. To calculate relative quantitation between all the samples studied, the target RNA levels for one sample are used as the basis for comparative results (calibrator). Quantitation relative to the "calibrator" can be obtained using the standard curve method or the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System).

To evaluate the tissue distribution, and the level of CSGs in normal and tumor tissue, total RNA was extracted from normal tissues, tumor tissues, and from tumors and the corresponding matched normal tissues. Subsequently, first strand cDNA was prepared with reverse transcriptase and the polymerase chain reaction was done using primers and Taqman probe specific to the CSG. The results were analyzed using the ABI PRISM 7700 Sequence Detector. The absolute numbers are relative levels of expression of the CSG compared to the calibrator.

#### **Comparative Examples**

Similar mRNA expression analysis for genes coding for the diagnostic markers PSA (Prostate Specific Antigen) and PLA2 (Phospholipase A2) was performed for comparison. PSA is currently the only cancer screening marker available in clinical laboratories. When the panel of normal pooled tissues was analyzed, PSA was expressed at very high levels in prostate, with a very low expression in breast and testis. After analysis of more than 55 matching samples from 14 different tissues, the data corroborated the tissue specificity seen with normal tissue samples. PSA expression was compared in cancer and normal adjacent tissue for 12 matching samples of prostate tissue. The relative levels of PSA were higher in 10 cancer samples (83%). Clinical data

- 16 -

recently obtained support the utilization of PLA2 as a staging marker for late stages of prostate cancer. mRNA expression data described herein showed overexpression of the mRNA in 8 out of the 12 prostate matching samples analyzed (66%). PLA2 had high levels of mRNA expression in small intestine, prostate, liver, and pancreas.

**Measurement of SEQ ID NO:3; Clone ID 1341701; Gene ID 29634 (Cln106)**

Absolute numbers are depicted in Table 2 as relative levels of expression of Cln106 (SEQ ID NO:3) in 12 normal different tissues. All the values are compared to normal testis (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

**Table 2: Relative levels of Cln106 Expression in Pooled Samples**

| <b>Tissue</b>   | <b>NORMAL</b> |
|-----------------|---------------|
| Colon-Ascending | 110           |
| Endometrium     | 0             |
| Kidney          | 0             |
| Liver           | 0             |
| Ovary           | 0             |
| Pancreas        | 0             |
| Prostate        | 16            |
| Small Intestine | 0             |
| Spleen          | 0             |
| Stomach         | 0             |
| Testis          | 1             |
| Uterus          | 0             |

The relative levels of expression in Table 2 show for the CSG Cln106 (SEQ ID NO:3), mRNA expression is more than 6 fold higher in the pool of normal ascending colon (110) compared with prostate (16). Testis, the calibrator, with a relative expression level of 1, is the only other tissue expressing the mRNA for Cln106 (SEQ ID NO:3). These results demonstrate that mRNA expression of this CSG is highly specific for colon.

- 17 -

The absolute numbers in Table 2 were obtained analyzing pools of samples of a particular tissue from different individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 3.

The absolute numbers in Table 3 are relative levels of expression of Cln106 (SEQ ID NO:3) in 57 pairs of matching samples. All the values are compared to normal testis (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

**Table 3: Relative levels of Cln106 Expression in Individual Samples**

| Sample ID | Tissue                      | Cancer | Matching Normal Adjacent |
|-----------|-----------------------------|--------|--------------------------|
| Sto AC93  | Stomach 1                   | 4      | 96                       |
| Sto AC99  | Stomach 2                   | 0.4    | 0.5                      |
| Sml 21XA  | Small Intestine 1           | 0      | 0                        |
| Sml H89   | Small Intestine 2           | 0.93   | 1.28                     |
| Cln B56   | Colon-Cecum(A) 1            | 317    | 101                      |
| Cln AS45  | Colon-Ascending(A) 2        | 316.3  | 146.5                    |
| Cln CM67  | Colon-Cecum(B) 3            | 481.0  | 217.5                    |
| Cln AS67  | Colon-Ascending(B) 4        | 858.1  | 220.6                    |
| Cln AS43  | Colon-Ascending(C) 5        | 1370   | 98                       |
| Cln AS46  | Colon-Ascending(C) 6        | 3051   | 375                      |
| Cln AS98  | Colon-Ascending(C) 7        | 26     | 42                       |
| Cln AS89  | Colon-Ascending(D) 8        | 524.6  | 11.0                     |
| Cln TX01  | Colon-Transverse(B) 9       | 2886.3 | 1992.0                   |
| Cln TX89  | Colon-Transverse(B) 10      | 146.0  | 35.9                     |
| Cln TX67  | Colon-Transverse(C) 11      | 2.9    | 421.7                    |
| Cln MT38  | Colon-Splenic Flexure(M) 12 | 1681   | 187                      |

- 18 -

|           |                         |        |        |
|-----------|-------------------------|--------|--------|
| Cln SG89  | Colon-Sigmoid(B)13      | 1063.8 | 31.1   |
| Cln SG67  | Colon-Sigmoid(C)14      | 8.5    | 9.4    |
| Cln SG33  | Colon-Sigmoid(C)15      | 264    | 549    |
| Cln SG45  | Colon-Sigmoid(D)16      | 580.0  | 114.6  |
| Cln B34   | Colon-Rectosigmoid(A)17 | 97     | 244    |
| Cln CXGA  | Colon-Rectum(A)18       | 45.1   | 273.4  |
| Cln RC67  | Colon-Rectum(B)19       | 2.7    | 20.0   |
| Cln C9XR  | Colon-Rectosigmoid(C)20 | 609    | 460    |
| Cln RS45  | Colon-Rectosigmoid(C)21 | 472.8  | 144.0  |
| Cln RC01  | Colon-Rectum(C)22       | 568    | 129    |
| Cln RC89  | Colon-Rectum(D)23       | 4.6    | 322.91 |
| Bld 46XK  | Bladder 1               | 0.2    | 0      |
| Bld 66X   | Bladder 2               | 1      | 1      |
| Bld 32XK  | Bladder 3               | 0.0    | 0.0    |
| Kid 126XD | Kidney 1                | 0      | 0      |
| Kid 12XD  | Kidney 2                | 0      | 0      |
| Kid 5XD   | Kidney 3                | 0.0    | 1.0    |
| Kid 6XD   | Kidney 4                | 0.0    | 0.0    |
| Kid 106XD | Kidney 5                | 0.4    | 0.0    |
| Liv 42X   | Liver 1                 | 0.0    | 0.0    |
| Liv 15XA  | Liver 2                 | 0.0    | 0.0    |
| Liv 94XA  | Liver 3                 | 0.0    | 0.0    |
| Lng AC69  | Lung 1                  | 2      | 0      |
| Lng BR94  | Lung 2                  | 0      | 0      |
| Lng 47XQ  | Lung 3                  | 0      | 0      |
| Mam 59X   | Mammary Gland 1         | 0      | 0      |
| Mam B011X | Mammary Gland 2         | 0      | 0      |
| Mam A06X  | Mammary Gland 3         | 0      | 0      |
| Ovr 103X  | Ovary 1                 | 0.04   | 2.08   |
| Ovr 130X  | Ovary 2                 | 0.1    | 2.76   |

- 19 -

|          |               |      |      |
|----------|---------------|------|------|
| Pan 71XL | Pancreas 1    | 4.08 | 0.1  |
| Pan 82XP | Pancreas 2    | 0    | 0    |
| Pro 12B  | Prostate 1    | 0.3  | 0    |
| Pro 23B  | Prostate 2    | 3    | 4    |
| Pro 13XB | Prostate 3    | 2    | 7    |
| Pro 34B  | Prostate 4    | 0.54 | 4.01 |
| Pro 20XB | Prostate 5    | 4.8  | 4.3  |
| Pro 65XB | Prostate 6    | 0.7  | 1.3  |
| Tst 39X  | Testis 1      | 2.78 | 0    |
| End 8XA  | Endometrium 1 | 0    | 0.2  |
| Utr 85XU | Uterus 1      | 1.26 | 0    |

0= Negative

When matching samples were analyzed, the higher levels of expression were in the colon, showing a high degree of tissue specificity for this tissue. These results confirm the tissue specificity results obtained with the panel of normal pooled samples (Table 2). Furthermore, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual were compared. This comparison provides an indication of specificity for the cancer stage (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 3 shows overexpression of Cln106 (SEQ ID NO:3) in 15 colon cancer tissues compared with their respective normal adjacent (colon samples #1, 2, 3, 4, 5, 6, 8, 9, 10, 12, 13, 16, 20, 21, and 22). There is overexpression in the cancer tissue for 65% of the colon matching samples tested (total of 23 colon matching samples). The matching sample Pan 71XL is a secondary cancer in pancreas, the primary cancer in that individual was a duodenal cancer.

Altogether, the high level of tissue specificity, plus the mRNA overexpression in 65% of the colon matching samples

- 20 -

tested are demonstrative of CSG Cln106 (SEQ ID NO:3) being a diagnostic marker for colon cancer.

**Measurement of SEQ ID NO:4; Clone ID 816257; Gene ID 406452 (Cln107)**

Absolute numbers as depicted in Table 4 are relative levels of expression of CSG Cln107 (SEQ ID NO:4) in 12 normal different tissues. All the values are compared to normal small intestine (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

**Table 4: Relative levels of Cln107 Expression in Pooled Samples**

| <b>Tissue</b>   | <b>NORMAL</b> |
|-----------------|---------------|
| Colon-Ascending | 3.2           |
| Endometrium     | 0             |
| Kidney          | 0.2           |
| Liver           | 0             |
| Ovary           | 0             |
| Pancreas        | 0             |
| Prostate        | 0.1           |
| Small Intestine | 1             |
| Spleen          | 0             |
| Stomach         | 0.3           |
| Testis          | 0             |
| Uterus          | 0             |

The relative levels of expression in Table 4 show that mRNA expression of the CSG Cln107 (SEQ ID NO:4) is more than 10 fold higher in the pool of normal ascending colon (3.2), five fold higher in small intestine (1), and 1.5 fold higher in stomach (0.3), compared with the next higher expressor (0.2 for kidney). Seven of the pooled tissues samples analyzed were negative and prostate showed a relative expression of 0.1 for Cln107 (SEQ ID NO:4). These results demonstrate that Cln107 mRNA expression is highly specific for colon, small intestine, and in a lower degree for stomach.

The absolute numbers in Table 4 were obtained analyzing pools of samples of a particular tissue from different

- 21 -

individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 5.

The absolute numbers in Table 5 are relative levels of expression of Cln107 (SEQ ID NO:4) in 57 pairs of matching samples. All the values are compared to normal small intestine (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

**Table 5: Relative levels of Cln107 Expression in Individual Samples**

| Sample ID | Tissue                         | Cancer | Matching<br>Normal<br>Adjacent |
|-----------|--------------------------------|--------|--------------------------------|
| Sto AC93  | Stomach 1                      | 8.9    | 13.4                           |
| Sto AC99  | Stomach 2                      | 6.0    | 0.9                            |
| Sml 21XA  | Small Intestine 1              | 1.07   | 1.42                           |
| Sml H89   | Small Intestine 2              | 0.97   | 4.13                           |
| Cln B56   | Colon-Cecum(A) 1               | 2      | 16                             |
| Cln AS45  | Colon-Ascending(A) 2           | 0.7    | 2.1                            |
| Cln CM67  | Colon-Cecum(B) 3               | 1.6    | 2.1                            |
| Cln AS67  | Colon-Ascending(B) 4           | 1.2    | 6.2                            |
| Cln AS43  | Colon-Ascending(C) 5           | 13.5   | 0.5                            |
| Cln AS46  | Colon-Ascending(C) 6           | 9.7    | 23.6                           |
| Cln AS98  | Colon-Ascending(C) 7           | 28.1   | 1.4                            |
| Cln AS89  | Colon-Ascending(D) 8           | 0.9    | 3.1                            |
| Cln TX01  | Colon-Transverse(B) 9          | 3.0    | 10.6                           |
| Cln TX89  | Colon-Transverse(B) 10         | 4.5    | 0.6                            |
| Cln TX67  | Colon-Transverse(C) 11         | 3.6    | 3.4                            |
| Cln MT38  | Colon-Splenic<br>Flexure(M) 12 | 4.0    | 2.6                            |
| Cln SG89  | Colon-Sigmoid(B) 13            | 4.7    | 0.9                            |

- 22 -

|           |                         |      |       |
|-----------|-------------------------|------|-------|
| ClN SG67  | Colon-Sigmoid(C)14      | 1.0  | 1.3   |
| ClN SG33  | Colon-Sigmoid(C)15      | 14.2 | 7.6   |
| ClN SG45  | Colon-Sigmoid(D)16      | 4.8  | 6.0   |
| ClN B34   | Colon-Rectosigmoid(A)17 | 3    | 2     |
| ClN CXGA  | Colon-Rectum(A)18       | 4.4  | 1.9   |
| ClN RC67  | Colon-Rectum(B)19       | 0.1  | 0.4   |
| ClN C9XR  | Colon-Rectosigmoid(C)20 | 5    | 3     |
| ClN RS45  | Colon-Rectosigmoid(C)21 | 11.4 | 4.6   |
| ClN RC01  | Colon-Rectum(C)22       | 1.8  | 2.3   |
| ClN RC89  | Colon-Rectum(D)23       | 0.1  | 5.35  |
| Bld 46XK  | Bladder 1               | 0.2  | 0     |
| Bld 66X   | Bladder 2               | 1    | 1     |
| Bld 32XK  | Bladder 3               | 0.1  | 0.1   |
| Kid 126XD | Kidney 1                | 0    | 0.02  |
| Kid 12XD  | Kidney 2                | 0.1  | 0.2   |
| Kid 5XD   | Kidney 3                | 0.3  | 0.0   |
| Kid 6XD   | Kidney 4-               | 0.1  | 0.1   |
| Kid 106XD | Kidney 5                | 0.0  | 0.1   |
| Liv 42X   | Liver 1                 | 7.9  | 0.002 |
| Liv 15XA  | Liver 2                 | 0.0  | 0.0   |
| Liv 94XA  | Liver 3                 | 0.0  | 0.0   |
| Lng AC69  | Lung 1                  | 1.6  | 0.2   |
| Lng BR94  | Lung 2                  | 0.4  | 0     |
| Lng 47XQ  | Lung 3                  | 0.78 | 0.2   |
| Mam 59X   | Mammary Gland 1         | 0.05 | 0.3   |
| Mam B011X | Mammary Gland 2         | 0.01 | 0.004 |
| Mam A06X  | Mammary Gland 3         | 0.22 | 0     |
| Ovr 103X  | Ovary 1                 | 0.01 | 0.01  |
| Ovr 130X  | Ovary 2                 | 0.09 | 0.1   |
| Pan 71XL  | Pancreas 1              | 2.51 | 2.81  |



- 23 -

|          |               |      |      |
|----------|---------------|------|------|
| Pan 82XP | Pancreas 2    | 0    | 0.62 |
| Pro 12B  | Prostate 1    | 0.3  | 0.1  |
| Pro 23B  | Prostate 2    | 0.3  | 0.2  |
| Pro 13XB | Prostate 3    | 0    | 0    |
| Pro 34B  | Prostate 4    | 0.04 | 0.22 |
| Pro 20XB | Prostate 5    | 0.4  | 0.1  |
| Pro 65XB | Prostate 6    | 0.0  | 0.1  |
| Tst 39X  | Testis 1      | 0.02 | 0.01 |
| End 8XA  | Endometrium 1 | 0.01 | 0.5  |
| Utr 85XU | Uterus 1      | 0.03 | 0    |

0= Negative

When matching samples were analyzed, the higher levels of expression were in colon, stomach, and small intestine, showing a high degree of tissue specificity for colon tissues. These results confirm the tissue specificity results obtained with normal pooled samples (Table 4). Furthermore, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual were compared. This comparison provides an indication of specificity for the cancer stage (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 5 shows overexpression of Cln107 (SEQ ID NO:4) in 11 colon cancer tissues compared with their respective normal adjacent (colon samples #5, 7, 10, 11, 12, 13, 15, 17, 18, 20, and 21). There is overexpression in the cancer tissue for 48% of the colon matching samples tested (total of 23 colon matching samples). The matching sample Pan 71XL is a secondary cancer in pancreas, the primary cancer in that individual was a duodenal cancer.

Altogether, the high level of tissue specificity, plus the mRNA overexpression in almost half of the colon, stomach, and small intestine matching samples tested are demonstrative

- 24 -

of CSG Cln107 (SEQ ID NO:4) being a diagnostic marker for colon cancer.

**Measurement of SEQ ID NO:5; Clone ID 775133; Gene ID 24508 (Cln108)**

The absolute numbers shown in Table 6 are relative levels of expression of CSG Cln108 (SEQ ID NO:5) in 12 normal different tissues. All the values are compared to normal small intestine (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

**Table 6: Relative levels of Cln108 Expression in Pooled Samples**

| <b>Tissue</b>   | <b>NORMAL</b> |
|-----------------|---------------|
| Colon-Ascending | 2846.5        |
| Endometrium     | 1             |
| Kidney          | 5.5           |
| Liver           | 18.7          |
| Ovary           | 3.4           |
| Pancreas        | 198.1         |
| Prostate        | 1024          |
| Small Intestine | 810.8         |
| Spleen          | 32.2          |
| Stomach         | 9981.2        |
| Testis          | 0             |
| Uterus          | 294.1         |

The relative levels of expression in Table 6 show that mRNA expression of CSG Cln108 (SEQ ID NO:5) is more than 10 fold higher in the pool of normal ascending colon (2846.5) and almost ten fold higher in stomach (9981.2), compared to the expression level in any other tissue analyzed. These results demonstrate that mRNA expression of this CSG is also highly specific for colon and stomach.

The absolute numbers in Table 6 were obtained analyzing pools of samples of a particular tissue from different individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 7.

- 25 -

The absolute numbers depicted in Table 7 are relative levels of expression of Cln108 (SEQ ID NO:5) in 57 pairs of matching samples. All the values are compared to normal small intestine (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

**Table 7: Relative levels of Cln108 Expression in Individual Samples**

| Sample ID | Tissue                      | Cancer   | Matching Normal Adjacent |
|-----------|-----------------------------|----------|--------------------------|
| Sto AC93  | Stomach 1                   | 28696    | 34842                    |
| Sto AC99  | Stomach 2                   | 21523    | 30862                    |
| Sml 21XA  | Small Intestine 1           | 2944     | 964.4                    |
| Sml H89   | Small Intestine 2           | 244.5    | 3513.2                   |
| Cln B56   | Colon-Cecum(A) 1            | 27242    | 24637                    |
| Cln AS45  | Colon-Ascending(A) 2        | 5827.0   | 8771.0                   |
| Cln CM67  | Colon-Cecum(B) 3            | 4251.0   | 4684.0                   |
| Cln AS67  | Colon-Ascending(B) 4        | 564.0    | 1949.0                   |
| Cln AS43  | Colon-Ascending(C) 5        | 50310    | 10949                    |
| Cln AS46  | Colon-Ascending(C) 6        | 246044   | 120073                   |
| Cln AS98  | Colon-Ascending(C) 7        | 40442    | 17482                    |
| Cln AS89  | Colon-Ascending(D) 8        | 5730.0   | 1581.0                   |
| Cln TX01  | Colon-Transverse(B) 9       | 22281.0  | 114784.0                 |
| Cln TX89  | Colon-Transverse(B) 10      | 11026.0  | 1639.0                   |
| Cln TX67  | Colon-Transverse(C) 11      | 17004.0  | 11654.0                  |
| Cln MT38  | Colon-Splenic Flexure(M) 12 | 77589    | 31620                    |
| Cln SG89  | Colon-Sigmoid(B) 13         | 140339.0 | 49617.0                  |
| Cln SG67  | Colon-Sigmoid(C) 14         | 4951.0   | 7905.0                   |
| Cln SG33  | Colon-Sigmoid(C) 15         | 60875    | 120490                   |

- 26 -

|           |                         |         |         |
|-----------|-------------------------|---------|---------|
| Cln SG45  | Colon-Sigmoid(D)16      | 30437.0 | 47267.0 |
| Cln B34   | Colon-Rectosigmoid(A)17 | 5848    | 5861    |
| Cln CXGA  | Colon-Rectum(A)18       | 13877.0 | 9787.0  |
| Cln RC67  | Colon-Rectum(B)19       | 1703.0  | 26589.0 |
| Cln C9XR  | Colon-Rectosigmoid(C)20 | 2458    | 19071   |
| Cln RS45  | Colon-Rectosigmoid(C)21 | 95523   | 61939   |
| Cln RC01  | Colon-Rectum(C)22       | 98891.0 | 80047.0 |
| Cln RC89  | Colon-Rectum(D)23       | 17.0    | 1775    |
| Bld 46XK  | Bladder 1               | 0       | 8       |
| Bld 66X   | Bladder 2               | 397     | 44      |
| Bld 32XK  | Bladder 3               | 0.0     | 16.0    |
| Kid 126XD | Kidney 1                | 32      | 22      |
| Kid 12XD  | Kidney 2                | 6       | 0       |
| Kid 106XD | Kidney 3                | 4.0     | 33.0    |
| Liv 42X   | Liver 1                 | 4783    | 0       |
| Liv 15XA  | Liver 2                 | 4.0     | 10.0    |
| Liv 94XA  | Liver 3                 | 159.0   | 21.0    |
| Lng AC69  | Lung 1                  | 222     | 295     |
| Lng BR94  | Lung 2                  | 112     | 0       |
| Lng 47XQ  | Lung 3                  | 30      | 69      |
| Lng AC66  | Lung 4                  | 29      | 137     |
| Mam 59X   | Mammary Gland 1         | 56      | 0       |
| Mam B011X | Mammary Gland 2         | 54      | 31      |
| Mam A06X  | Mammary Gland 3         | 12      | 0       |
| Ovr 103X  | Ovary 1                 | 37      | 0       |
| Pan 71XL  | Pancreas 1              | 13203   | 4163    |
| Pan 82XP  | Pancreas 2              | 39.1    | 0       |
| Pro 12B   | Prostate 1              | 386     | 88      |
| Pro 23B   | Prostate 2              | 250     | 23      |
| Pro 13XB  | Prostate 3              | 92      | 731     |

- 27 -

|           |               |       |        |
|-----------|---------------|-------|--------|
| Pro 34B   | Prostate 4    | 33.3  | 265.7  |
| Pro 20XB  | Prostate 5    | 454.6 | 1908.9 |
| Pro 65XB  | Prostate 6    | 733.5 | 922.0  |
| End 8XA   | Endometrium 1 | 5     | 92     |
| Utr 85XU  | Uterus 1      | 98.9  | 21.8   |
| Utr 23XU  | Uterus 2      | 35.3  | 0      |
| Utr 135XO | Uterus 3      | 39.2  | 43.8   |
| Utr 141XO | Uterus 4      | 212.1 | 55.9   |

0= Negative

When matching samples were analyzed, the higher levels of expression were in colon and stomach, showing a high degree of tissue specificity for these two tissues. These results confirm the tissue specificity results obtained with normal pooled samples (Table 6). Furthermore, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual were compared. This comparison provides an indication of specificity for the cancer stage (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 7 shows overexpression of CSG Cln108 (SEQ ID NO:5) in 13 colon cancer tissues compared with their respective normal adjacent (colon samples #1, 5, 6, 7, 8, 9, 10, 11, 12, 13, 18, 21, and 22). There is overexpression in the cancer tissue for 56% of the colon matching samples tested (total of 23 colon matching samples). The matching sample Pan 71XL is a secondary cancer in pancreas, the primary cancer in that individual was a duodenal cancer.

Altogether, the high level of tissue specificity, plus the mRNA overexpression in more than half of the colon, stomach, and small intestine matching samples tested are demonstrative of this CSG, Cln108 (SEQ ID NO:5), also being a diagnostic marker for colon cancer.

**Measurement of SEQ ID NO:7; Clone ID 2348122; Gene ID 23371 (Cln109)**

The absolute numbers depicted in Table 8 are relative levels of expression of CSG Cln109 (SEQ ID NO:7) in 12 normal different tissues. All the values are compared to normal ovary (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

**Table 8: Relative levels of Cln109 Expression in Pooled Samples**

| <b>Tissue</b>   | <b>NORMAL</b> |
|-----------------|---------------|
| Colon-Ascending | 28.8          |
| Endometrium     | 0.45          |
| Kidney          | 0.41          |
| Liver           | 0.72          |
| Ovary           | 0.07          |
| Pancreas        | 82.8          |
| Prostate        | 124.3         |
| Small Intestine | 626.4         |
| Spleen          | 1.2           |
| Stomach         | 12.05         |
| Testis          | 1.51          |
| Uterus          | 52.99         |

The relative levels of expression in Table 8 show that mRNA expression of CSG Cln109 (SEQ ID NO:7), is more than 5 fold higher in the pool of normal small intestine (626.4) compared to the expression level in any other tissue analyzed. These results demonstrate that Cln109 (SEQ ID NO:7) mRNA expression is highly specific for small intestine

The absolute numbers in Table 8 were obtained analyzing pools of samples of a particular tissue from different individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 9.

The absolute numbers depicted in Table 9 are relative levels of expression of Cln109 (SEQ ID NO:7) in 53 pairs of matching samples. All the values are compared to normal ovary (calibrator). A matching pair is formed by mRNA from the

- 29 -

cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

**Table 9: Relative levels of Cln109 Expression in Individual Samples**

| Sample ID | Tissue                      | Cancer  | Matching Normal Adjacent |
|-----------|-----------------------------|---------|--------------------------|
| Sto AC93  | Stomach 1                   | 2574    | 1310                     |
| Sto AC99  | Stomach 2                   | 4153    | 5                        |
| Sml 21XA  | Small Intestine 1           | 2667    | 13663.8                  |
| Sml H89   | Small Intestine 2           | 57.8    | 904.29                   |
| Cln B56   | Colon-Cecum(A) 1            | 6794    | 299                      |
| Cln AS45  | Colon-Ascending(A) 2        | 814.6   | 105.8                    |
| Cln CM67  | Colon-Cecum(B) 3            | 294.6   | 36.1                     |
| Cln AS67  | Colon-Ascending(B) 4        | 2.2     | 26.3                     |
| Cln AS43  | Colon-Ascending(C) 5        | 111     | 377                      |
| Cln AS46  | Colon-Ascending(C) 6        | 1180    | 352                      |
| Cln AS98  | Colon-Ascending(C) 7        | 1075    | 92                       |
| Cln AS89  | Colon-Ascending(D) 8        | 14022.7 | 87.5                     |
| Cln TX01  | Colon-Transverse(B) 9       | 1027.6  | 282.1                    |
| Cln TX89  | Colon-Transverse(B) 10      | 2.5     | 23.7                     |
| Cln TX67  | Colon-Transverse(C) 11      | 0.1     | 72.3                     |
| Cln MT38  | Colon-Splenic Flexure(M) 12 | 372     | 88                       |
| Cln SG89  | Colon-Sigmoid(B) 13         | 179.2   | 33.4                     |
| Cln SG67  | Colon-Sigmoid(C) 14         | 85.0    | 94.7                     |
| Cln SG33  | Colon-Sigmoid(C) 15         | 5461    | 377                      |
| Cln SG45  | Colon-Sigmoid(D) 16         | 762.7   | 15.9                     |
| Cln B34   | Colon-Rectosigmoid(A) 17    | 460     | 1                        |
| Cln RC67  | Colon-Rectum(B) 18          | 64.5    | 136.2                    |
| Cln C9XR  | Colon-Rectosigmoid(C) 19    | 441     | 34                       |
| Cln RS45  | Colon-Rectosigmoid(C) 20    | 1931    | 195                      |

- 30 -

|           |                   |        |        |
|-----------|-------------------|--------|--------|
| Cln RC01  | Colon-Rectum(C)21 | 72.8   | 19.1   |
| Cln RC89  | Colon-Rectum(D)22 | 4.8    | 90.2   |
| Bld 46XK  | Bladder 1         | 4      | 3      |
| Bld 66X   | Bladder 2         | 1      | 0      |
| Bld 32XK  | Bladder 3         | 0.1    | 307.6  |
| Kid 126XD | Kidney 1          | 0      | 2      |
| Kid 12XD  | Kidney 2          | 3      | 16     |
| Kid 5XD   | Kidney 3          | 0.0    | 0.3    |
| Kid 6XD   | Kidney 4          | 18.5   | 1.2    |
| Liv 42X   | Liver 1           | 21     | 0.03   |
| Liv 15XA  | Liver 2           | 0.5    | 0.4    |
| Liv 94XA  | Liver 3           | 0.4    | 0.0    |
| Lng AC69  | Lung 1            | 0.1    | 0      |
| Lng BR94  | Lung 2            | 3      | 0      |
| Lng 60XL  | Lung 3            | 0.1    | 0      |
| Mam 59X   | Mammary Gland 1   | 0      | 4      |
| Mam B011X | Mammary Gland 2   | 8      | 13     |
| Mam A06X  | Mammary Gland 3   | 4.7    | 9.6    |
| Pan 71XL  | Pancreas 1        | 8902.5 | 1428.2 |
| Pan 82XP  | Pancreas 2        | 0.2    | 9.3    |
| Pro 12B   | Prostate 1        | 9      | 20     |
| Pro 23B   | Prostate 2        | 191    | 88     |
| Pro 13XB  | Prostate 3        | 12     | 460    |
| Pro 34B   | Prostate 4        | 3.2    | 80.4   |
| Tst 39X   | Testis 1          | 29.9   | 0      |
| End 8XA   | Endometrium 1     | 0.3    | 21     |
| Utr 85XU  | Uterus 1          | 244.7  | 592.2  |
| Ovr 63A   | Ovary 1           | 11.4   | 0      |
| Ovr A1C   | Ovary 2           | 68.4   | 0      |

0= Negative



- 31 -

When matching samples were analyzed, the higher levels of expression were in small intestine, colon and stomach, showing a high degree of tissue specificity for these three colon tissues. These results confirm the tissue specificity results obtained with normal pooled samples for small intestine (Table 8). Furthermore, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual were compared. This comparison provides an indication of specificity for the cancer stage (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 9 shows overexpression of CSG, Cln109 (SEQ ID NO:7) in 15 colon cancer tissues compared with their respective normal adjacent (colon samples #1, 2, 3, 6, 7, 8, 9, 12, 13, 15, 16, 17, 19, 20, and 21). There is overexpression in the cancer tissue for 68% of the colon matching samples tested (total of 22 colon matching samples). The matching sample Pan 71XL is a secondary cancer in pancreas, the primary cancer in that individual was a duodenal cancer.

Altogether, the high level of tissue specificity, plus the mRNA overexpression in more than half of the colon, stomach, and small intestine matching samples tested are demonstrative of CSG Cln109 (SEQ ID NO:7) being a diagnostic marker for colon cancer. The amino acid sequence encoded by the open reading frame of Cln109 is depicted in SEQ ID NO:10.

- 32 -

**What is claimed is:**

1. A method for diagnosing the presence of colon cancer in a patient comprising:

(a) measuring levels of CSG in a sample of cells, tissue or bodily fluid obtained from the patient; and

(b) comparing the measured levels of CSG with levels of CSG in a sample of cells, tissue or bodily fluid obtained from a control, wherein an increase in measured levels of CSG in the patient versus the CSG levels in the control is associated with the presence of colon cancer.

2. A method of diagnosing metastatic colon cancer in a patient comprising:

(a) measuring levels of CSG in a sample of cells, tissue, or bodily fluid obtained from the patient; and

(b) comparing the measured levels of CSG with levels of CSG in a sample of cells, tissue, or bodily fluid obtained from a control, wherein an increase in measured CSG levels in the patient versus the CSG levels in the control is associated with a cancer which has metastasized.

3. A method of staging colon cancer in a patient comprising:

(a) identifying a patient suffering from colon cancer;

(b) measuring levels of CSG in a sample of cells, tissue, or bodily fluid obtained from the patient; and

(c) comparing the measured levels of CSG with levels of CSG in a sample of cells, tissue, or bodily fluid obtained from a control, wherein an increase in the measured levels of CSG versus the levels of CSG in the control is associated with a cancer which is progressing and a decrease in the measured levels of CSG versus the levels of CSG in the control is associated with a cancer which is regressing or in remission.

- 33 -

4. A method of monitoring colon cancer in a patient for the onset of metastasis comprising:

- (a) identifying a patient having colon cancer that is not known to have metastasized;
- (b) periodically measuring CSG levels in samples of cells, tissue, or bodily fluid obtained from the patient; and
- (c) comparing the periodically measured levels of CSG with levels of CSG in cells, tissue, or bodily fluid obtained from a control, wherein an increase in any one of the periodically measured levels of CSG in the patient versus the levels of CSG in the control is associated with a cancer which has metastasized.

5. A method of monitoring changes in a stage of colon cancer in a patient comprising:

- (a) identifying a patient having colon cancer;
- (b) periodically measuring levels of CSG in samples of cells, tissue, or bodily fluid obtained from the patient; and
- (c) comparing the measured levels of CSG with levels of CSG in a sample of the same cells, tissue, or bodily fluid of a control, wherein an increase in any one of the periodically measured levels of CSG versus levels of CSG in the control is associated with a cancer which is progressing in stage and a decrease in any one of the periodically measured levels of CSG versus the levels of CSG in the control is associated with a cancer which is regressing in stage or in remission.

6. The method of claim 1, 2, 3, 4 or 5 wherein the CSG comprises SEQ ID NO:3, 4, 5 or 7.

## SEQUENCE LISTING

<110> Macina, Roberto A.  
Yang, Fei  
Sun, Yongming

<120> A Novel Method of Diagnosing, Monitoring and Staging  
Colon Cancers

<130> DEX-0035

<140>

<141>

<150> 60/086,266

<151> 1998-05-21

<160> 10

<170> PatentIn Ver. 2.0

<210> 1

<211> 487

<212> DNA

<213> Homo sapiens

<400> 1

```
tctgcatctg gccctcccag tgcacctgtt caatcccagc ycctccctga cctgtacaaa 60
tacacctgag gaccggctcg agcccagact tcttgcccct gctctgcact ctcagggtatt 120
ccctgtctctt actccaaaaa gatggaccca ggtccgaagg ggcaactgcca ctgtggggggg 180
catggccatc ctccagggtca ctgcgggcga acccctggcc atggcccagg gccctgcggg 240
ccaccccttg gccatggccc agggccctgc gggcaacccc ctggccatgg ccaggggcc 300
tgcgggcctc cccctggcca tggcccaggt caccacccc ctggtccaca tcaactgagga 360
agtagaagaa aacaggacac aagatggcaa gcctgagaga attgcccagc tgacctggaa 420
tgaggcctaa accacaatct tctcttccta ataaacagcc tcctagagge cacattctat 480
tctttaa 487
```

<210> 2

<211> 739

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (693)

<220>

<221> unsure

<222> (696) .. (699)

<220>

<221> unsure

<222> (703) .. (705)

<220>

<221> unsure

<222> (708)

<220>

<221> unsure

<222> (710) .. (716)

<220>

<221> unsure

<222> (718)

<220>

<221> unsure

<222> (723) .. (726)

<220>

<221> unsure

<222> (728)

<220>

<221> unsure

<222> (732)

<220>

<221> unsure

<222> (737)

<400> 2

```
tctgaaactg tcagttccac cagcaactgct tggatactgg taagtttcca gggggctgct 60
ttgcatctga aactgtcagc cccagaatgt tgacagtcgc tctcctagcc cttctctgtg 120
cctcagcctc tggcaatgcc attcaggcca ggtcttcctc ctatagtga gagtatggaa 180
gtggtggtgg aaagcgattc tctcattctg gcaaccagtt ggacggcccc atcaccgccc 240
tccgggtccg agtcaacaca tactacatcg taggtcttca ggtgcgctat ggcaaggtgt 300
ggagcgacta tgtgggtggc cgcaacggag acctggagga gatctttctg caccctgggg 360
aatcagtgat ccaggtttcc gggaagtaca agtggtacct gaagaagctg gtatttgtga 420
cagacaaggg ccgctatctg tcttttggga aagacagtgg cacaagtttc aatgccgtcc 480
ccttgcaccc caacaccgtg ctccgcttca tcagtggccg gtctgggttct ctcatcgatg 540
ccattggcct gcactgggat gtttacccca ctagctgcag cagatgctga gcctcctctc 600
cttggcaggg gcactgtgat gaggagtaag aactccctta tactaacc ccacccaaat 660
ggctcaataa aaaaatatgg ttaaggctaa aanaaaanng gar.nnaanan nnnnnntnca 720
aannnnantt cncctgnta 739
```

<210> 3  
 <211> 428  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> (391)

<400> 3  
 aattgtccgg ggtcaaacag aggagagcat gaatgagagt catcctcgca agtgtgcaga 60  
 gtctttttgag atgtgggag atcgtgactc ccactgtagg cgccctaagt ttgaagggca 120  
 tccccctgag tcttggaagt ggatccttgc accggtcatt ctttatatct gtgaaaggat 180  
 cctccggttt taccgctccc agcagaaggt tgtgattacc aaggttgtta tgcacccatc 240  
 caaagttttg gaattgcaga tgaacaagcg tggcttcagc atggaagtgg ggcagtatat 300  
 ctttggttaat tgcacctcaa tctctctcct ggggaatggca tcccttttact ttgacctctg 360  
 ctccagagga agatttcttc ttcattcata tncgagcagc aggggacttg acagaaaatc 420  
 tataaggg 428

<210> 4  
 <211> 1347  
 <212> DNA  
 <213> Homo sapiens

<400> 4  
 ggaaaacccc tgagcacaaa gcaagaggca tcgaagcccc ctcggggatg cccgcaagcc 60  
 aacagggggtg tctgtcgggtg ggagtacttc cgctgcgtc ctctgcggtt cagggcccca 120  
 gacgagcccc agcaggccca agtcccccat gtctggggct gggagggtggc tggggccccc 180  
 gcaactgaggc tgcagaagtc ccagtcactc gatctgctgg aaaggagag ggagagtgtc 240  
 ctgcgccggg agcaagaggt ggcagaggag cggagaaatg ctctcttccc agaggtcttc 300  
 tccccaacgc cagatgagaa ctctgaccag aactccagga gctcctccca ggcattccggc 360  
 atcactgggca gttactcggg gtctgagctc ccttcttcca gccccatcca cctacactca 420  
 aacgtggcgt ggacagtga agatccagt gacagtgtc ctcccgggca gagaaagaag 480  
 gagcaatggt acgtggcat caaccctcg gacggatatc actcagaggt cctggaagcc 540  
 atacgggtga ccgctcacia gaacgccatg gcagagcgt gggaatcccg catctacgcc 600  
 agtgaggagg atgactgagc ctcgggatgg ggcgcccacc ccctgccctg ccctgacct 660  
 cgtgggaact gccaaagacca tcgccaagcc cccaccctag gaaatgggtc ctaggtccag 720  
 gatccaagaa ccacagctca tctgccaaca atcccaccat gggcacattt gggactgttg 780  
 gggttttctg ttccttcttc atcttcttt agaaatgttt ctgccttttg ggtctaaagc 840  
 ttttggggat gaaatgggga cccctgctga ttctttctgc ttctaagact ttgccaaatg 900  
 ccctgggtct aagaaagaaa gagaccgct cctccacttt caggtgtaat ttgcttccgc 960  
 tagtctgagg gcagaggcag cggtcaaaaga ggggtggcaca gatcgagca ccttgagggg 1020  
 ctgcgggtct gagggaggag acactcagct cctccctctg agaagtccca agctgagagg 1080  
 ggagacctgc ccttttccaa ccctgggaaa ccatccagtc tgagggagga ggccaaactc 1140  
 ccagtgtctg gggtccctgt gcagccctca aacccttcac cttggtgcac ccagccacac 1200  
 ctggtggaca caaagctctc acatcgatag gatcccatga ggatgggtccc ctccacctgg 1260  
 gagaaaagtg acccagttta ggagctggag ggggggtcttt gtccccacc cccaaactgc 1320

cctgaaataa acctggagtg agctgcc

1347

&lt;210&gt; 5

&lt;211&gt; 1249

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (1034)..(1046)

&lt;400&gt; 5

```

ggcagagcct gcgcagggca ggagcagctg gccactggc ggcccgcaac actccgtctc 60
accctctggg cccactgcat ctagaggagg gccgtctgtg aggccactac cctccagca 120
actgggaggt gggactgtca gaagctggcc caggggtgtg gtcagctggg tcagggacct 180
aacggcacct ggctgggacc acctcgccctt ctccatcgaa gcaggggaag tgggagcctc 240
gagccctcgg gtggaagctg accccaagcc acccttcacc tggacaggat gagagtgtca 300
ggtgtgcttc gccctcctggc cctcatcttt gccatagtca cgacatggat gtttattcga 360
agctacatga gcttcagcat gaaaaccatc cgtctgccac gctggctggc ctgcccacc 420
aaggagatcc aggttaaaaa gtacaagtgt ggccctcatca agccctgccc agccaactac 480
tttgcttta aaatctgcag tggggccgcc aacgtcgtgg gccctactat gtgctttgaa 540
gaccgcatga tcatgagtcc tgtgaaaaac aatgtgggca gaggcctaaa catcgccctg 600
gtgaatggaa ccacgggagc tgtgctggga cagaagtcac ttgacatgta ctctggagat 660
gttatgcacc tagtgaaatt ccttaaagaa attccggggg gtgactggg gctgggtggc 720
tctacgacg atccagggac caaatgaac gatgaaagca ggaaactctt ctctgacttg 780
gggagttcct acgcaaaaca actgggcttc cgggacagct ggggtctcat aggagccaaa 840
gacctcaggg gtaaaaagccc ctttgagcag ttcttaaaga acagcccaga cacaaacaaa 900
tacgagggat ggccagagct gctggagatg gagggctgca tgcccccga gccattttag 960
ggtggctgtg gctcttcctc agctaggggc ctgaagaagc tctgacctga cttaggagtc 1020
agagcccggc agnnnnnnnn nnnnnnnnnn nnnnnntgct gcgtggaagg tgctgcaggt 1080
ccttgacgc tgtgtcgcgc ctctcctcct cggaacaga accctcccac agcacatcct 1140
acccggaaga ccagcctcag agggctcctt tggaaccagc tgtctgtgga gagaatgggg 1200
tgctttcgtc agggactgct gacggctggt cctgaggaag gacaaactc 1249

```

&lt;210&gt; 6

&lt;211&gt; 1220

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 6

```

gctttctgca cctcattcca catcaggagc gtttttggag aaagctgcac tctgttgagc 60
tccagggcgc agtggaggga gggagtgaag gagctctctg taccgaagga aagtgcagct 120
gagactcaga caagattaca atgaaccaac tcagcttctt gctgtttctc atagcgacca 180
ccagaggatg gactacagat gaggctaata ctacttcaa ggaatggacc tgttcttcgt 240
ctccatctct gcccagaagc tgcaaggaaa tcaaagacga atgtcctagt gcatttgatg 300
gcctgtattt tctccgcact gagaatgggt ttatctacca gaccttctgt gacatgacct 360
ctgggggtgg cgctgggacc ctgggtggcca gcgtgcacga gaatgacatg cgtgggaagt 420
gcacgggtgg cgatcgctcg tccagtcagc agggcagcaa agcagtctac ccagaggggg 480

```

```

acggcaactg ggccaactac aacacctttg gatctgcaga ggcggccacg agcgaatgact 540
acaagaaccc tggctactac gacatccagg ccaaggacct gggcatctgg cacgtgcca 600
ataagtcacc catgcagcac tggagaaaca gctccctgct gaggtaccgc acggacactg 660
gcttcctcca gacactggga cataatctgt ttggcatcta ccagaaatat ccagtgaatat 720
atggagaagg aaagtgttgg actgacaacg gcccggtgat ccctgtgggc tatgattttg 780
gcgacgcccc gaaaacagca tcttattact caccctatgg ccagcgggaa ttcactgcgg 840
gattttgttca gttcagggtt ttaataacg agagagcagc caacgccttg tgtgctggaa 900
tgagggtcac cggatgtaac actgagcacc actgcattgg tggaggagga tactttccag 960
aggccagtc cagcagtggt ggagattttt ctggttttga ttggagtggg tatggaactc 1020
atgtttggtta cagcagcagc cgtgagataa ctgaggcagc tgtgcttcta tctatcgtt 1080
gagagttttt tgggagggaa ccagacctc tctcccaac catgagatcc caaggatgga 1140
gaacaactta ccagtagct agaattgtta tggcagaaga gaaaacaata aatcatattg 1200
actcaaaaaa aaaaaaaaaaag 1220

```

&lt;210&gt; 7

&lt;211&gt; 2796

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 7

```

cggctcgagg gacaggatga ggcccggcct ctcattttct ctagcccttc tgttcttctt 60
tggccaagct gcaggggatt tgggggatgt gggacctcca attcccagcc cgggttccag 120
ccctttccca ggtgttgact ccagctccag ctccagctcc agctccaggt cgggtccag 180
ctccagccgc agcttaggca gcggagggtc tgtgtccag ttgttttcca atttcaccgg 240
ctccgtggat gaccgtggga cctgccagt ctctgtttcc ctgccagaca ccacctttcc 300
cgtggacaga gtggaacgct tggaaattcac agctcatgtt ctttctcaga agtttgagaa 360
agaactttcc aaagtggagg aatatgtcca attaattagt gtgtatgaaa agaaactgtt 420
aaacctaact gtccgaattg acatcatgga gaaggatacc atttcttaca ctgaactgga 480
cttcgagctg atcaaggtag aagtgaagga gatggaaaaa ctggtcatac agctgaagga 540
gagtttttgt ggaagctcag aaattgttga ccagctggag gtggagataa gaaatatgac 600
tctcttggtt gagaagcttg agacactaga caaaaacaat gtccttgcca ttcgccgaga 660
aatcgtggct ctgaagacca agctgaaaga gtgtgaggcc tctaaagatc aaaacacccc 720
tgtctgtccac cctctcccca ctccaggag ctgtggtcat ggtggtgtgg tgaacatcac 780
caaacctctt gtggttcagc tcaactggag agggttttct tatctatatg gtgcttgggg 840
tagggattac tctccccagc atccaaacaa aggactgtat tgggtggcgc cattgaatac 900
agatgggaga ctgttggagt attatagact gtacaacaca ctggatgatt tgcatttcta 960
tataaatgct cgagagtggc ggatcaccta tggccaaggt agtggtagag cagttttaca 1020
caacaacatg tacgtcaaca tgtacaacac cgggaatatt gccagagtta acctgaccac 1080
caacacgatt gctgtgactc aaactctccc taatgctgcc tataataacc gcttttcata 1140
tgctaattgt gcttggcaag atattgactt tgctgtggat gagaatggat tgtgggttat 1200
ttattcaact gaagccagca ctggttaacat ggtgattagt aaactcaatg acaccacact 1260
tcaggtgcta aacacttggc ataccaagca gtataaacca tctgcttcta acgccttcat 1320
ggtatgtggg gttctgtatg ccaccgta c tatgaacacc agaacagaag agatttttta 1380
ctattatgac acaaacacag ggaaagaggg caaactagac attgtaatgc ataagatgca 1440
ggaaaaagtg cagagcatta actataaccc ttttgaccag aaactttatg tctataacga 1500
tggttacctt ctgaattatg atctttctgt ctgacagaag cccagtaag ctgttttagga 1560
gttaggggtg aagagaaatg gtttgttgaa aaaatagctt tctccactta cttagatata 1620
tgcaggggtg tctaaaagtg tgttcatttt gcagcaatgt ttaggtgcat agttctacca 1680

```



```

cactagagat ctaggacatt tgtcttgatt tggtagagttc tcttgggaat catctgcctc 1740
ttcaggcgca ttttgcaata aagtctgtct agggtagggat tgtcagaggt ctaggggcac 1800
tgtgggccta gtgaagccta ctgtgaggag gcttcactag aagccttaaa ttaggaatta 1860
aggaacttaa aactcagtat ggcgtctagg gattctttgt acaggaaata ttgccaatg 1920
actagtctc atccatgtag caccactaat tcttccatgc ctggaagaaa cctggggact 1980
tagttaggta gattaatata tggagctcct cgagggacca aatctccaac tttttttcc 2040
cctcactaca cctggaatga tgctttgtat gtggcagata agtaaatttg gcatgcttat 2100
atattctaca tctgtaaagt gctgagtttt atggagagag gcctttttat gcattaaatt 2160
gtacatggca aataaatccc agaaggatct gtagatgagg cacctgcttt ttcttttctc 2220
tcattgtcca ccttactaaa agtcagtaga atcttctacc tcataacttc ctccaaagg 2280
cagctcagaa gattagaacc agacttacta accaattcca cccccacca accccttct 2340
actgcctact ttaaaaaaat taatagtttt ctatggaact gatctaagat tagaaaaatt 2400
aattttcttt aatttcatta tggactttta tttacatgac tctaagacta taagaaaatc 2460
tgatggcagt gacaaagtgc taqcatttat tgttatctaa taaagacctt ggagcatatg 2520
tgcaacttat gagtgtatca gttgttgcat gtaatttttg cctttgttta agcctggaac 2580
ttgtaagaaa atgaaaattt aatttttttt tctaggacga gctatagaaa agctattgag 2640
agtatctagt taatcagtgc agtagttgga aaccttgctg gtgtatgtga tgtgcttctg 2700
tgcttttgaa tgactttatc atctagtctt tgtctgtttt tcttttgatg tccaagtcct 2760
agtctatagg attggcagtt taaatgcttt actccc 2796

```

&lt;210&gt; 8

&lt;211&gt; 2331

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (675)

&lt;400&gt; 8

```

tttatcacgg gctcaactgc aacaaaacac ttccttgaca gctccacaaa ctcaggccac 60
agttaggaat caacaatatt ccacagcagc ccagatgcaa gtggaacaac accctcatct 120
gccactcca caacctcagg tcttgagaaa tctacaacct cagcatcag tccaggctca 180
actgaaataa caacgttacc tggcagtacc acaacaccag gcctcagtga ggcattctacc 240
accttctaca gttagccccag atcaccagac caaacactct cacctgccag catgagaagc 300
tccagcatca gtggagaacc caccagcttg tatagccaag cagagtcaac acacacaaca 360
gcgttccctg ccagcaccac cacctcaggc ctcagtcagg aatcaacaac tttccacagt 420
aagccaggct caactgagac aacactgtcc cctggcagca tcacaacttc atcttttgct 480
caagaattta ccaccctca tagccaacca ggctcagctc tgtcaacagt gtcacctgcc 540
agcaccacag tgccaggcct tagtgaggaa tctaccacct tctacagcag ccaggctca 600
actgaaacca cagcgttttc tcacagcaac acaatgtcca ttcatagtca acaatctaca 660
ccttccctg acagnccagg cttcactcac acagtgttac ctgccacct cacaaccaca 720
gacattggtc aggaatcaac agccttccac agcagctcag acgcaactgg aacaacaccc 780
ttacctgccc gctccacagc ctcagacctt gttggagaac ctacaacttt ctacatcagc 840
ccatccccctt cttacacaac actctttcct gcgagttcca gcacatcagg ctcactgag 900
gaatctacca ccttccacac cagtccaagc ttcacttcta caattgtgtc tactgaaagc 960
ctggaacact tagcaccagg gttctgccag gaaggacaaa tttggaatgg aaaacaatgc 1020
gtctgtcccc aaggctacgt tggctaccag tgcttgctcc ctctggaatc ctccctgta 1080

```

```

gaaacccccgg aaaaactcaa cgccacttta ggtatgacag tgaaagtgcac ttacagaaat 1140
ttcacagaaa agatgaatga cgcacccctcc caggaatacc agaacttcag taccctcttc 1200
aagaatcgga tggatgtcgt tttgaagggc gacaatcttc ctcatatag aggggtgaac 1260
attcggagat tgctcaacgg tagcatcgtg gtcaagaacg atgtcactct ggaggcagac 1320
tacacttttag agtatgagga actgtttgaa aacctggcag agattgtaaa ggccaagatt 1380
atgaatgaaa ctagaacaac tcttcttgat cctgattcct gcagaaaggc catactgtgc 1440
tatagtgaag aggacacttt cgtggattca tcggtgactc cgggctttga cttccaggag 1500
caatgcaccc agaaggctgc cgaaggatat acccagttct actatgtgga tgtcttggat 1560
gggaagctgg cctgtgtgaa caagtgcacc aaaggaacga agtcgcaaat gaactgtaac 1620
ctgggcacat gtcagctgca acgcagtggc cccccgctgc ctgtgcccac atacgaacac 1680
aacttggtac tggggagaga cctgtgaatt caacatcgcc aagagcctcg tgtatgggat 1740
cgtgggggct gtgatggcgg tgctgctgct cgcattgac atcctaatac tcttattcag 1800
cctatcccag agaaaacggc acagggaaca gtatgatgtg cctcaagagt ggcgaaagga 1860
aggcaccctt ggcatcttcc agaagacggc catctgggaa gaccagaatc tgaggagag 1920
cagattcggc cttgagaacg cctacaacaa cttccggccc accctggaga ctgttgactc 1980
tggcacagag ctccacatcc agaggccgga gatggtagca tccactgtgt gagccaacgg 2040
gggctctcca cctcatctca gctctgttca ggagagctgc aaacacagag cccaccacaa 2100
gctcggggg cgggtcaaga ggagaccgaa gtcaggccct gaagccggtc ctgctctgag 2160
ctgacagact tggccagtc cctgcctgtg ctctgtctgg ggaaggctgg gggctgtaag 2220
cctctccatc cgggagcttc cagactccca gaagcctcgg caccctgtc tctcctggg 2280
tggtcctcca ctctggaatt tccctaccaa taaaagcaaa tctgaaagct c 2331

```

&lt;210&gt; 9

&lt;211&gt; 909

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 9

```

gaggaggtgg gcgccaacag acaggcgatt aatgcggctc ttaccagggc aaccaggact 60
acagtataca ttgtggacat tcaggacata gattctgcag ctggggcccg acctcactcc 120
tacctcgatg cctactttgt cttcccacaa gggctcagccc tgacccttga tgagctgagt 180
gtgatgatcc ggaatgatca ggactcgctg acgcagctgc tgcagctggg gctgggtggtg 240
ctgggctccc aggagagcca ggagtcagac ctgtcgaaac agctcatcag tgtcatcata 300
ggattgggag tggctttgct gctggctcct gtgatcatga ccatggcctt cgtgtgtgtg 360
cggaagagct acaaccggaa gcttcaagct atgaaggctg ccaaggaggc caggaagaca 420
gcagcagggg tgatgccctc agcccctgcc atcccaggga ctaacatgta caaactgag 480
cgagccaacc ccatgctgaa cctcccacaa aaagacctgg gcttgagta cctctctccc 540
tccaatgacc tggactctgt cagcgtcaac tccctggacg acaactctgt ggatgtggac 600
aagaacagtc aggaatcaa ggagcacagg ccaccacaca caccaccaga gccagatcca 660
gagccctga gcgtggctct gttaggacgg caggcaggcg caagtggaca gctggagggg 720
ccatcctaca ccaacgctgg cctggacacc acggacctgt gacaggggcc cccactcttc 780
tggacccctt gaagaggccc taccacaccc taactgcacc tgtctccctg gagatgaaaa 840
tatatgacgc tgccctgcct cctgcttttg gccaatcacg gcagacaggg gttggggaaa 900
tattttatt
909

```

&lt;210&gt; 10

&lt;211&gt; 510

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 10

Met Arg Pro Gly Leu Ser Phe Leu Leu Ala Leu Leu Phe Phe Leu Gly  
 1 5 10 15

Gln Ala Ala Gly Asp Leu Gly Asp Val Gly Pro Pro Ile Pro Ser Pro  
 20 25 30

Gly Phe Ser Pro Phe Pro Gly Val Asp Ser Ser Ser Ser Phe Ser Ser  
 35 40 45

Ser Ser Arg Ser Gly Ser Ser Ser Ser Arg Ser Leu Gly Ser Gly Gly  
 50 55 60

Ser Val Ser Gln Leu Phe Ser Asn Phe Thr Gly Ser Val Asp Asp Arg  
 65 70 75 80

Gly Thr Cys Gln Cys Ser Val Ser Leu Pro Asp Thr Thr Phe Pro Val  
 85 90 95

Asp Arg Val Glu Arg Leu Glu Phe Thr Ala His Val Leu Ser Gln Lys  
 100 105 110

Phe Glu Lys Glu Leu Ser Lys Val Arg Glu Tyr Val Gln Leu Ile Ser  
 115 120 125

Val Tyr Glu Lys Lys Leu Leu Asn Leu Thr Val Arg Ile Asp Ile Met  
 130 135 140

Glu Lys Asp Thr Ile Ser Tyr Thr Glu Leu Asp Phe Glu Leu Ile Lys  
 145 150 155 160

Val Glu Val Lys Glu Met Glu Lys Leu Val Ile Gln Leu Lys Glu Ser  
 165 170 175

Phe Gly Gly Ser Ser Glu Ile Val Asp Gln Leu Glu Val Glu Ile Arg  
 180 185 190

Asn Met Thr Leu Leu Val Glu Lys Leu Glu Thr Leu Asp Lys Asn Asn  
 195 200 205

Val Leu Ala Ile Arg Arg Glu Ile Val Ala Leu Lys Thr Lys Leu Lys  
 210 215 220

Glu Cys Glu Ala Ser Lys Asp Gln Asn Thr Pro Val Val His Pro Pro  
 225 230 235 240

Pro Thr Pro Gly Ser Cys Gly His Gly Gly Val Val Asn Ile Ser Lys  
 245 250 255

Pro Ser Val Val Gln Leu Asn Trp Arg Gly Phe Ser Tyr Leu Tyr Gly  
 260 265 270

Ala Trp Gly Arg Asp Tyr Ser Pro Gln His Pro Asn Lys Gly Leu Tyr  
 275 280 285

Trp Val Ala Pro Leu Asn Thr Asp Gly Arg Leu Leu Glu Tyr Tyr Arg  
 290 295 300

Leu Tyr Asn Thr Leu Asp Asp Leu Leu Leu Tyr Ile Asn Ala Arg Glu  
 305 310 315 320

Leu Arg Ile Thr Tyr Gly Gln Gly Ser Gly Thr Ala Val Tyr Asn Asn  
 325 330 335

Asn Met Tyr Val Asn Met Tyr Asn Thr Gly Asn Ile Ala Arg Val Asn  
 340 345 350

Leu Thr Thr Asn Thr Ile Ala Val Thr Gln Thr Leu Pro Asn Ala Ala  
 355 360 365

Tyr Asn Asn Arg Phe Ser Tyr Ala Asn Val Ala Trp Gln Asp Ile Asp  
 370 375 380

Phe Ala Val Asp Glu Asn Gly Leu Trp Val Ile Tyr Ser Thr Glu Ala  
 385 390 395 400

Ser Thr Gly Asn Met Val Ile Ser Lys Leu Asn Asp Thr Thr Leu Gln  
 405 410 415

Val Leu Asn Thr Trp Tyr Thr Lys Gln Tyr Lys Pro Ser Ala Ser Asn  
 420 425 430

Ala Phe Met Val Cys Gly Val Leu Tyr Ala Thr Arg Thr Met Asn Thr  
 435 440 445

Arg Thr Glu Glu Ile Phe Tyr Tyr Tyr Asp Thr Asn Thr Gly Lys Glu  
 450 455 460

Gly Lys Leu Asp Ile Val Met His Lys Met Gln Glu Lys Val Gln Ser  
 465 470 475 480

Ile Asn Tyr Asn Pro Phe Asp Gln Lys Leu Tyr Val Tyr Asn Asp Gly  
 485 490 495

Tyr Leu Leu Asn Tyr Asp Leu Ser Val Leu Gln Lys Pro Gln .  
500 505 510

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/10498

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12Q 1/68; G01N 33/53, 33/574

US CL : 435/4, 6, 7.1

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/4, 6, 7.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Scisearch, HCAPLUS, medline, biosis, membase, wpids, jicst-eplus, biobusiness, biotechds, phin, phic, embal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages     | Relevant to claim No. |
|-----------|--|-----------------------|
| X         | WO 96/39419 A1 (HUMAN GENOME SCIENCES, INC.) 12<br>December 1996, see entire document. | 1-5                   |

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

|   |  |
|---|--|
| * Special categories of cited documents:  | *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  |
| *A* document defining the general state of the art which is not considered to be of particular relevance  | *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone   |
| *E* earlier document published on or after the international filing date  | *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | *A* document member of the same patent family  |
| *O* document referring to an oral disclosure, use, exhibition or other means  |  |
| *P* document published prior to the international filing date but later than the priority date claimed  |  |

Date of the actual completion of the international search

16 AUGUST 1999

Date of mailing of the international search report

10 SEP 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

NANCY JOHNSON

Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/10498

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☒ Claims Nos.: 6  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
  
The sequence listing in computer readable form did not comply with required standards. The disc could not be preprocessed. Thus, a search of claim 6, drawn to SEQ ID NO:3, 4, 5 or 7, could not be carried out.
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
  
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐  
☐

- The additional search fees were accompanied by the applicant's protest.  
No protest accompanied the payment of additional search fees.

**THIS PAGE BLANK (USPTO)**